Cloning, characterization of β-glucosidase from Furfurilactobacillus rossiae in bioconversion and its efficacy
Thi Ngoc Anh Tran,Jinnatun Nahar,Jin-Kyu Park,Mohanapriya Murugesan,Jae-Heung Ko,Jong Chan Ahn,Deok-Chun Yang,Ramya Mathiyalagan,Dong Uk Yang
DOI: https://doi.org/10.1007/s00203-024-04148-4
IF: 2.667
2024-10-04
Archives of Microbiology
Abstract:Minor ginsenosides produced by β-glucosidase are interesting biologically and pharmacologically. In this study, new ginsenoside-hydrolyzing glycosidase from Furfurilactobacillus rossiae DCYL3 was cloned and expressed in Escherichia coli strain BL21. The enzyme converted Rb1 and Gyp XVII into Rd and compound K following the pathways: Rb1→Rd and Gyp XVII→F2→CK, respectively at optimal condition: 40 °C, 15 min, and pH 6.0. Furthermore, we examined the cytotoxicity, NO production, ROS generation, and gene expression of G ynostemma extract (GE) and bioconverted G ynostemma extract (BGE) in vitro against A549 cell lines for human lung cancer and macrophage RAW 264.7 cells for antiinflammation, respectively. As a result, BGE demonstrated significantly greater toxicity than GE against lung cancer at a dose of 500 μg/mL but in normal cells showed lower toxicity. Then, we indicated an enhanced generation of ROS, which may be boosting cancer cell toxicity. By blocking the intrinsic way, BGE increased p53 , Bax , Caspase 3 , 9 , and while Bcl2 is decreased. At 500 μg/mL, the BGE sample was less toxic in normal cells and decreased the LPS-treated NO and ROS level to reduce inflammation. In addition, BGE inhibited the expression of pro-inflammatory genes COX-2 , iNOS , IL-6 , and IL-8 in RAW 264.7 cells than the sample of GE. In conclusion, FrBGL3 has considerable downstream applications for high-yield, low-cost, effective manufacture of minor ginsenosides. Moreover, the study's findings imply that BGE would be potential materials for anti-cancer and anti-inflammatory agent after consideration of future studies.
microbiology